Primecap Management Co. CA Trims Stake in BioMarin Pharmaceutical Inc. $BMRN

Primecap Management Co. CA lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 3.4% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 15,229,287 shares of the biotechnology company’s stock after selling 542,886 shares during the period. Primecap Management Co. CA owned 0.08% of BioMarin Pharmaceutical worth $824,818,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. AQR Capital Management LLC raised its holdings in BioMarin Pharmaceutical by 90.7% in the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock valued at $306,429,000 after buying an additional 2,654,768 shares during the period. Norges Bank acquired a new stake in shares of BioMarin Pharmaceutical during the second quarter valued at about $112,352,000. Viking Global Investors LP raised its stake in shares of BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after acquiring an additional 1,488,552 shares during the period. LSV Asset Management lifted its holdings in shares of BioMarin Pharmaceutical by 2,445.5% in the 3rd quarter. LSV Asset Management now owns 845,500 shares of the biotechnology company’s stock worth $45,792,000 after acquiring an additional 812,284 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter worth approximately $35,202,000. 98.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on BMRN shares. Guggenheim cut their target price on BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating on the stock in a research report on Wednesday. Oppenheimer lowered their price target on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a research report on Tuesday. Wells Fargo & Company boosted their price objective on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Barclays started coverage on BioMarin Pharmaceutical in a research note on Wednesday, January 28th. They set an “overweight” rating and a $80.00 target price on the stock. Finally, Truist Financial lifted their target price on BioMarin Pharmaceutical from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 23rd. Fifteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $87.43.

BioMarin Pharmaceutical Price Performance

Shares of BMRN opened at $61.44 on Thursday. The firm has a market capitalization of $11.80 billion, a price-to-earnings ratio of 34.52, a PEG ratio of 0.68 and a beta of 0.26. The firm’s fifty day simple moving average is $58.72 and its 200-day simple moving average is $56.12. BioMarin Pharmaceutical Inc. has a twelve month low of $50.76 and a twelve month high of $73.51. The company has a current ratio of 5.21, a quick ratio of 3.10 and a debt-to-equity ratio of 0.10.

More BioMarin Pharmaceutical News

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q4 earnings beat and record/strong revenue growth driven by Voxzogo, which supports near-term fundamentals. Q4 Highlights
• Positive Sentiment: Sanford C. Bernstein raised its price target to $94 and keeps an “outperform” rating, signaling bullish conviction from a major shop. Bernstein PT Raise
• Positive Sentiment: TD Cowen/Phil Nadeau maintained a Buy rating with a $120 price target, highlighting confidence in multi‑year growth and recent strategic moves. TD Cowen Note
• Neutral Sentiment: Bank of America reiterated a Buy but trimmed its target to $97, reflecting confidence in long-term upside while acknowledging nearer-term pressures. BofA Note
• Neutral Sentiment: Management will present at four investor conferences in March, which could provide additional investor visibility and updates on pipeline strategy. Investor Conferences
• Neutral Sentiment: Public short-interest data for February is effectively zero/unclear (likely reporting artifact) and does not appear to be a driver of today’s move.
• Negative Sentiment: BioMarin said it will voluntarily withdraw Roctavian (its hemophilia gene therapy) from the market — a material strategic setback that raises questions about near- and medium-term revenue trajectory and risk profile. Roctavian Withdrawal
• Negative Sentiment: Several analysts trimmed targets or issued more cautious notes (Guggenheim lowered to $86, HC Wainwright cut to $55 and moved to Neutral), creating mixed sell-side signals and short-term pressure. Analyst Revisions

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.